Eric Vivier provides a longitudinal analysis of immune responses, including immune cell phenotyping and assessments of the soluble factors present in the blood and broncho-alveolar lavage fluid (BALF) of patients at various stages of COVID-19 severity: paucisymptomatic, pneumonia and acute respiratory distress syndrome (ARDS).

He reports an increase in soluble C5a levels proportional to COVID-19 severity and high levels of C5aR1 expression in blood and pulmonary myeloid cells, supporting a role for the C5a-C5aR1 axis in the pathophysiology of ARDS.

Anti-C5aR1 therapeutic monoclonal antibodies (mAbs) prevented C5a-mediated human myeloid cell recruitment and activation, and inhibited acute lung injury (ALI) in human C5aR1 knockin mice.

These results support C5a-C5aR1 axis blockade as a means of limiting myeloid cell infiltration in damaged organs and preventing the excessive lung inflammation and endothelialitis associated with ARDS in COVID-19 patients.

>> Register:

Ver Webinar anteriores

Donna Farber: Respiratory immunity and COVID-19 

Donna Farber discusses the development of lung-localized immune responses and the role of tissue resident memory T cells in protective immunity to respiratory viruses, in mouse models of influenza infection and in human lungs,  including recent findings on the impact of age on human lung immunity.  These concepts will be discussed in the context of respiratory immunity in SARS-CoV2 infection and our studies identifying potential immune correlates of disease severity in COVID-19.
Donna Farber is the George H Humphreys, II Professor of Surgical Sciences (in Surgery) and Professor of Microbiology and Immunology at Columbia University. The webinar is moderated by Henry Mwandumba, Professor of Immunology and Infectious Diseases at the University of Malawi College of Medicine and Deputy Director of the Malawi Liverpool Wellcome Trust Clinical Research Programme (MLW) in Blantyre, Malawi.

Ver Webinar anteriores

Date: May 11, 2020
Time: 16:00 (UTC+2)

Adaptive Immunity: Memory, Protection and Immunopathology in COVID-19

What do we know about the adaptive immune reaction to Sars-CoV-2? Why do humans react so heterogeneously to Sars-CoV-2? Does the adaptive immune system provide protection and for how long? How can we challenge the system with a vaccine to establish longlasting, efficient immunity?

Watch the interview now and join the live webinar on Monday, May 11!

Presenter: Andreas Radbruch

As Scientific Director, Andreas Radbruch is in charge of the thematic orientation of the biomedical research at the DRFZ since Professor Andreas Radbruch is a biologist by training, having done his PhD at the Genetics Institute of Cologne University. He has been the Director of the German Rheumatism Research Centre Berlin, a Leibniz institute, since 1996 and Professor of Rheumatology at the Charité Medical School of the Humboldt University of Berlin since 1998.
Andreas Radbruch is the President of the European Federation of Immunological Societies (EFIS).

Moderator: Rita Carsetti

Rita Carsetti is the Head of the Diagnostic Immunology Unit and of the B cell pathophysiology Research Unit of the Bambino Gesù Children Hospital IRCCS in Rome. She has spent a large part of her scientific career in Germany, at the Max-Planck for Immunobiology in Freiburg. Thanks to the long experience in basic research combined with the clinical involvement, she has contributed to the understanding of important basic mechanisms of human B cell biology and function in health and disease. In the last years, she has been involved in several projects related to the development of the immune system in children and adults and the changes due to different types of immunodeficiency. She is also involved in increasing the knowledge and public awareness on vaccines and vaccination and collaborates with patient associations. She is a founding member of the European B cell network and is the chair of the PUB committee of the IUIS.

Ver Webinar anteriores

Webinar on April 24

Giuseppe Ippolito: The Global Scientific Response to COVID-19

Date: April 24, 2020
Time: 18:00 (UTC+2)

Ver Webinar anteriores